Table of Content

1. Market Introduction and Scope
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. Executive Insights and Key Takeaways
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy
2.4. Snippet by Application
2.5. Snippet by End-User
2.6. Snippet by Region
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Cancer
3.1.1.2. Rising Adoption of Combination Therapies
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Adverse Effects Associated with Various Oncology Therapies
3.1.2.2. High Cost of Treatment for Oncology Therapy
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Personalized and Precision Oncology
3.1.3.2. XX
3.1.4. Impact Analysis
4. Strategic Insights and Industry Outlook
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.10. Pricing Analysis and Price Dynamics
5. Oncology Therapy Market, By Therapy
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
5.1.2. Market Attractiveness Index, By Therapy
5.2. Chemotherapy*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Alkylating Agents
5.2.4. Antimetabolites
5.2.5. Anti-tumor Antibiotics
5.2.6. Topoisomerase Inhibitors
5.2.7. Others
5.3. Targeted Therapy
5.3.1. Monoclonal Antibodies
5.3.2. Small Molecule Inhibitors
5.4. Immunotherapy
5.4.1. Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)
5.4.2. CAR-T Cell Therapy
5.4.3. Cancer Vaccines
5.4.4. Cytokines
5.4.5. Others
5.5. Hormonal Therapy
5.5.1. Anti-estrogens
5.5.2. Aromatase Inhibitors
5.5.3. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists/Antagonists
5.5.4. Others
5.6. Radiation Therapy
5.7. Others
6. Oncology Therapy Market, By Application
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
6.1.2. Market Attractiveness Index, By Application
6.2. Breast Cancer*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lung Cancer
6.4. Blood Cancer
6.5. Prostate Cancer
6.6. Colorectal Cancer
6.7. Stomach Cancer
6.8. Liver Cancer
6.9. Esophageal Cancer
6.10. Cervical Cancer
6.11. Ovarian Cancer
6.12. Bladder Cancer
6.13. Head and Neck Cancer
6.14. Skin Cancer (Melanoma)
6.15. Pancreatic Cancer
6.16. Kidney Cancer
6.17. Others
7. Oncology Therapy Market, By End-User
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cancer Research Centers
7.4. Specialty Clinics
7.5. Others
8. Oncology Therapy Market, By Regional Market Analysis and Growth Opportunities
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.5. South America
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. Brazil
8.5.6.2. Argentina
8.5.6.3. Rest of South America
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. Competitive Landscape and Market Positioning
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. Company Profiles
10.1. Amgen Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. AstraZeneca
10.3. Bayer AG
10.4. Merck & Co., Inc.
10.5. Johnson & Johnson Services, Inc.
10.6. F. Hoffmann-La Roche Ltd
10.7. Novartis AG
10.8. GSK plc
10.9. Eli Lilly and Company
10.10. Rigel Pharmaceuticals, Inc.
LIST NOT EXHAUSTIVE
11. Assumptions and Research Methodology
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. Appendix
12.1. About Us and Services
12.2. Contact Us